Vaccitech PLC
F:2AB
Relative Value
The Relative Value of one
2AB
stock under the Base Case scenario is
hidden
EUR.
Compared to the current market price of 0.57 EUR,
Vaccitech PLC
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
2AB Competitors Multiples
Vaccitech PLC Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| UK |
|
Vaccitech PLC
F:2AB
|
23.3m EUR | 0 | -0.5 | 1.3 | 1.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
394.1B USD | 6.6 | 167.9 | 16.3 | 23.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
203.3B USD | 5.5 | 26.4 | 15.1 | 15.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
188.3B USD | 6.5 | 23.2 | 15.8 | 15.8 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
119.5B USD | 10.2 | 32.5 | 23.9 | 24.9 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.8B USD | 5.7 | 18.1 | 15.4 | 17.6 | |
| AU |
|
CSL Ltd
ASX:CSL
|
89B AUD | 4 | 20.6 | 13.8 | 17.2 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42.4B EUR | 14 | 33 | 56.2 | 57.8 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.2 | -61.8 | -66.7 | -60.2 |